Li et al. [40] reported that SIRT1 down-regulation improved the acetylation and subsequent transcriptional activity of p53 in CML progenitors, thus enhanced elimination of CML stem cells in combination with imatinib. This evidence concerns the gene TP53 and chronic myelogenous leukemia, BCR-ABL1 positive.